Article
Recognition of impaired atomoxetine metabolism because of low CYP2D6 activity.
Pediatric neurology - 1 Sept 2010
ter Laak Maureen A, Temmink Alphons H, Koeken Ankie, van 't Veer Nils E, van Hattum Paul R M, Cobbaert Christa M
Abstract excerpt
Ten out of 100 children treated for attention deficit hyperactivity disorder with standard doses of atomoxetine were selected by a neurologist for cytochrome P450 2D6 and cytochrome P450 2C19 genotyping, based on late response (>9 weeks) and adverse effects (gastrointestinal problems, sleeping disorders, malaise, inactivity, and mood instabilities). After genotyping, eight children were confirmed to have...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.